Stryker Co. (NYSE:SYK) Shares Sold by Colonial Trust Advisors

Colonial Trust Advisors lessened its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,404 shares of the medical technology company's stock after selling 760 shares during the quarter. Colonial Trust Advisors' holdings in Stryker were worth $10,587,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of SYK. Chicago Capital LLC lifted its position in Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares during the last quarter. Zhang Financial LLC boosted its stake in shares of Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after purchasing an additional 40,784 shares during the period. Appleton Partners Inc. MA grew its holdings in Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after purchasing an additional 1,400 shares during the last quarter. Metis Global Partners LLC lifted its stake in Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after purchasing an additional 1,561 shares during the last quarter. Finally, US Bancorp DE boosted its position in shares of Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after buying an additional 976 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Stryker Stock Down 1.9 %

NYSE SYK traded down $6.64 during trading on Tuesday, hitting $346.78. The company's stock had a trading volume of 519,705 shares, compared to its average volume of 1,356,003. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market cap of $132.36 billion, a PE ratio of 44.69, a P/E/G ratio of 2.93 and a beta of 0.93. The business's 50 day simple moving average is $374.63 and its 200-day simple moving average is $373.58.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business posted $3.46 EPS. On average, equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on SYK shares. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Canaccord Genuity Group boosted their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $423.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.